CONTENTS
· Faculty
· Scientific Agenda
· Welcome
· Accreditation
· Who Should Attend?
· Objectives
· Registration
· General Information
· Hotel
  Accommodations
· Congress

Mario Boccadoro, MD
University of Torino
Torino, Italy

Christian Buske, MD
Ludwig-Maximilians-University
Munich, Germany

Joan Bladé, MD
University of Barcelona
Barcelona, Spain

Patrice Carde, MD, PhD
Institut Gustave-Roussy
Villejuif, France

Sylvain Choquet, MD
CHU La Pitie Salpetriere Hospital
Toulouse, France

Bertrand Coiffier, MD
Hospices Civils de Lyon
Lyon, France

Francesco D’Amore, MD
Aarhus University
Arhus, Denmark

Jan Delabie, MD
Rikshospitalet-Radiumhospitalet HF
University of Oslo
Oslo, Norway

Claire Dearden, MD
The Royal Marsden Hospital and Institute of Cancer Research
Surrey, United Kingdom

Meletios A. Dimopoulos, MD
University of Athens
Athens, Greece

Andreas Engert, MD
Cologne University
Cologne, Germany

Günter Fingerle-Rowson, MD, PhD
Klinikum der Universitaet zu Koeln,
Cologne, Germany

Bertram Glass, MD
University Hospital Gottingen
Gottingen, Germany

Andre P. Goy, MD
Hackensack University Medical Center
Hackensack, New Jersey, United States

Corinne Haioun, MD
Henri Mondor Hospital
Créteil, France

Jean-Luc Harousseau, MD
University Hospital Hotel-Dieu
Nantes, France

Dieter Hoelzer, MD
University Hospital of Frankfurt
Frankfurt, Germany

Tim M. Illidge, MD, PhD, FRCR
Christie Hospital
Manchester University
Manchester, United Kingdom

Nicolas Ketterer, MER
Multidisciplinary Oncology Centre
University Hospital of Lausanne
Lausanne, Switzerland

Eva Kimby, MD, PhD
Karolinska Institute
Huddinge University Hospital
Stockholm, Sweden

David G. Maloney, MD, PhD
Fred Hutchinson Cancer Research Center
Seattle, Washington, United States

Emilio Montserrat, MD
University of Barcelona
Barcelona, Spain

Owen O’Connor, MD, PhD
Memorial Sloan-Kettering Cancer Center
New York, New York, United States

Steve Proctor, MD
University of Newcastle-upon-Tyne
Tyne, United Kingdom

Andreas Rosenwald, MD
University of Wuerzburg
Wuerzburg, Germany

Norbert Schmitz, MD, PhD
Asklepios Klinik St. Georg
Hamburg, Germany

Anna Tasidou, MD
Evangelismos Hospital
Athens, Greece

Friday, 23 February 2007

13:00
Welcome and introduction

Session I: Myeloma
Moderator: Meletios A. Dimopoulos, MD

13:10
Treatment of newly diagnosed patients with multiple myeloma
Joan Bladé, MD

13:30
Novel salvage therapies in myeloma
Mario Boccadoro, MD

13:50
The role of high dose therapy in myeloma in the era of new therapies
Jean-Luc Harousseau, MD

14:10
Benefits and risks of bisphosphonate therapy in myeloma
Meletios A. Dimopoulos, MD

14:30
Panel discussion

14:45
Chair summary and take home points

14:50
Break

Session II: Lymphoma Biology
Moderator: Meletios A. Dimopoulos, MD

15:20
Pathobiology of primary mediastinal B-cell lymphoma
Anna Tasidou, MD

15:40
Biology of mantle cell lymphoma
Andreas Rosenwald, MD

16:00
Familial forms and tendencies in lymphoid malignancies
Sylvain Choquet, MD

16:20
Separating high risk from intermediate or low risk patients with advanced stage lymphoma: The Follicular Lymphoma International Prognostic Index (FLIPI)
Christian Buske, MD

16:40
Panel discussion

16:55
Chair summary and take home points

17:00
Adjourn

Saturday, 24 February 2007

Session III: Chronic Lymphocytic Leukemia
Moderator: Emilio Montserrat, MD

9:00
Is CLL a curable disorder?
Emilio Montserrat, MD

9:20
Antibody therapy in CLL
Eva Kimby, MD, PhD

9:40
Minimal residual disease status as an outcome measure of CLL therapy
Claire Dearden, MD

10:00
Oblimersen therapy: Long-term follow-up results
Günter Fingerle-Rowson, MD, PhD

10:20
Panel discussion

10:35
Chair summary and take home points

10:40
Break

Session IV: Indolent Non-Hodgkin’s Lymphoma
Moderator: Eva Kimby, MD, PhD

11:00
Role of radioimmunotherapy in management of NHL
Tim M. Illidge, MD, PhD, FRCR

11:20
Should every patient with indolent lymphoma receive maintenance anti CD20 antibody therapy?
David G. Maloney, MD, PhD

11:40
Diagnosis, prognosis and treatment of transformed lymphoma
Nicolas Ketterer, MER

12:00
Bortezomib alone and in combination for indolent lymphoma
Andre P. Goy, MD

12:20
Allogenic transplantation in follicular lymphoma
David G. Maloney, MD, PhD

12:40
Panel discussion

12:55
Chair summary and take home points

13:00
Lunch

Session V: Aggressive Non-Hodgkin’s Lymphoma
Moderator: Bertrand Coiffier, MD

14:50
Update on anti CD20 antibody therapy – CHOP
Bertrand Coiffier, MD

15:10
RICOVER follow up: What is the best treatment for diffuse large B-cell lymphoma?
Bertram Glass, MD

15:30
Prevention of central nervous system occurrence in NHL
Corinne Haioun, MD

15:50
Burkett’s lymphoma
Dieter Hoelzer, MD

16:10
Panel discussion

16:25
Chair summary and take home points

16:30
Adjourn

Sunday, 25 February 2007

Session VI: T Cell Lymphomas
Moderator: Owen O’Connor, MD, PhD

9:00
Classification of T cell lymphoma
Jan Delabie, MD

9:20
Review of T cell lymphoma treatment
Francesco D’Amore, MD

9:40
New therapies in T cell lymphoma
Owen O’Connor, MD, PhD

10:00
Auto and allo transplant in T cell lymphoma
Norbert Schmitz, MD, PhD

10:20
Panel discussion

10:35
Chair summary and take home points

10:40
Break

Session VII: Hodgkin’s Lymphoma
Moderator: Moderator invited

11:10
What is the standard chemotherapy regimen in localized Hodgkin's disease?
Partice Carde, MD, PhD

11:30
State-of-the-art immunotherapy in Hodgkin’s lymphoma
Andreas Engert, MD

11:50
Hodgkin’s lymphoma in elderly patients
Steve Proctor, MD

12:10
Panel discussion

12:25
Chair summary and take home points

12:30
Adjourn

We are pleased to invite you to attend the 3rd European Congress on Hematologic Malignancies: From Clinical Science to Clinical Practice, to be held 23-25 February 2007 in Athens, Greece. The focus of this Congress is to provide a forum to review the state-of-the-art and present new data on the diagnosis and management of myeloma, lymphoma and related disorders as well as to give attendees the opportunity to exchange ideas with world-renowned opinion leaders. Last year’s Congress, held in Barcelona, was attended by more than 650 hematologists and oncologists from 48 countries, most of whom are directly involved in patient care. Their highly positive review of the educational content, quality of the speakers, and presentation excellence attests to the overall satisfaction of the attendees and the value of continuing with a comprehensive update on hematologic oncology management.

To complement the exceptional scientific experience, Athens offers the perfect setting for enjoyable after-hours relaxation. There are few places that evoke such a heady sense of cultural romance as Greece. The cradle of Western thought, literature, art, architecture and democracy gave birth to such beauties as Homer’s The Iliad, Sophocles’ Oedipus the King, the teachings of Plato and Socrates, the Parthenon, Zorba, the Olympics and souvlaki. It is a cultural red-carpet which Greeks are justifiably proud to roll out. We hope you will join us in this beautiful and historic city for a stimulating and enjoyable conference.

Imedex^®, Inc. is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.be.

3rd European Congress on Hematological Malignancies: From Clinical Science to Clinical Practice is designated for a maximum of 12 hours of European external CME credits. Each medical specialist should claim only those hours of credit that she/he actually spent in the educational activity.

EACCME credits are recognized by the American Medical Association toward the Physician’s Recognition Award (PRA). To convert EACCME credit to AMA PRA Category 1 credit, contact the AMA.

This program is designed for hematologists and oncologists in active clinical practice involved and/or interested in lymphoma, myeloma and related hematological disorders and their management. No specific knowledge other than a basic familiarity with the principles and practice of hematologic oncology is required for successful participation in this program.

After successfully completing this program, participants should be able to:

• Outline the basic biology of myeloma, lymphoma, and related plasma cell disorders
• Recommend the most appropriate management strategies for the various types and stages of lymphoma, myeloma and related disorders
• Identify promising new drugs and therapy combinations for the treatment of myeloma, lymphoma and related disorders
• Discuss advantages and disadvantages of PET in both treatment and monitoring
• Comment of the role of radioimmunotherapy in hematological malignancies
• Gain insight into the practical management of challenging cases within hematology

Click here to register online.

Regular (If payment received by 14 February 2007) . . . . . . .€ 399
Full/Onsite (If payment received after 14 February 2007) . . . € 499
Resident/Student/Nurse* . . . . . . . . . . . . . . . . . . . . . . . . . .€ 199
*proof of eligibility must accompany registration

To Register
You may register by 14 February 2007 at online or call Imedex at +1 (678) 242 0906. Registration confirmations will be issued before the Congress.

To qualify for special registration fees, registration and full payment must be received by Imedex by the dates specified.

Payment
To pre-register, registration and payment must be received no later than 15 February 2007. Please register on-site after this date. Registration fees must be remitted by credit card, check, or wire transfer. Checks should be payable to Imedex. To pay via wire transfer, you must add €50 to each wire transaction to cover bank charges. Include the full name of the attendee and the name of the Congress: 273 Hematologic Malignancies. An attendee is not registered until full payment is received.

Wire to: Bank of America, NA London, 1 Alie Street E1ADE London UK, Swift Code: BOFAGB22, Sort Code: 165050 Beneficiary: Bank of America Domestic Deposit #5687, Account #: 600895687029, Reference: Imedex, Inc. Account # 10726-118, IBAN: GB89 BOFA 1650 5095 6870 29.

Registration Fee Inclusions
Registration fees include admittance to scientific sessions, Congress materials and all functions as specified in the program.

Cancellation
For registration fees to be refunded, written notice of cancellation must be received at Imedex by 14 February 2007. The amount of registration fees remitted, minus a €90 administrative charge, will be refunded after the conference. Substitutions are accepted with written notification. No refunds will be made if notice is received after 14 February 2007.

Imedex does not accept responsibility for covering travel, accommodation or any other costs incurred by registrants in the rare event that this program should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation. The event program content is subject to change without notice.

From a survey of the 2006 Congress attendees:

• 98% of respondents feel they increased their professional knowledge
• 90% of respondents have shared learned information with a colleague

More than half of respondents plan to change their disease management approach.
What will you change after this meeting?

Registration Hours
The Registration and Information Desk will be staffed:
Friday, 23 February 2007 . . . . . . . 10:00–17:30
Saturday, 24 February 2007 . . . . . 08:00–16:30
Sunday, 25 February 2007 . . . . . . 08:00–12:30

Pre-registration
To pre-register, registration and payment must be received no later than 14 February 2007. Please register on-site after this date.

Discounted Airfares
Contact Congress travel agent, Age of Travel, for assistance with your travel needs. Age of Travel can also accommodate pre- and post-
Congress extensions.
Tel.: +1 (800) 523 4954 or
+1 (404) 591 7120
Email: imedex@ageoftravel.com

Italian Participants
Fargo International Meetings & Conventions Srl has been appointed as the official agency for government authorization for Italian participants. You may contact them directly at:
Fargo International Meetings & Conventions SRL
Via Piattro Maroncelli 44/66, 50137 Firenze, Italy
Tel.: +39 055 600 555
Fax: +39 055 609 078

Congress Location & Hotel Accommodations
Divani Caravel Hotel
2, Vas. Alexandrou Avenue
Athens, Greece 16121
Tel: +30 210 7207000
Fax: +30 210 7236683

The completely renovated Divani Caravel Hotel, a member of The Leading Hotels of the World, is ideally situated in the heart of Athens. It is just minutes away from the business centre, the fashionable Kolonaki with its exclusive shopping, trendy cafes and restaurants as well as important museums such as the Museum of Cycladic Arts and the National Gallery.

For the convenience of attendees, a limited number of rooms have been reserved at a rate of €150 for single occupancy or €160 for double occupancy. This rate includes all taxes and daily breakfast. This rate is not guaranteed outside the conference dates.

Full prepayment for all nights requested is required at the time of booking. Reservations will not be confirmed without full prepayment.

For individual reservations, please submit a completed hotel reservation form. For group hotel reservations, groups should contact Imedex directly. Imedex will attempt to meet all accommodation requests, however it reserves the right to change the requested hotel to one of a similar category if unable to confirm the hotel described in this brochure.

          4325 Alexander Drive
          Alpharetta, GA 30022-3740 USA
          Tel.: +1 (770) 751 7332
          Fax: +1 (770) 751 7334
          Email: meetings@imedex.com
          Web: www.imedex.com